Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Minority Interest (2016 - 2017)

IGC Pharma has reported Minority Interest over the past 7 years, most recently at -$9007.0 for Q4 2017.

  • Quarterly Minority Interest changed 0.08% to -$9007.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$9007.0 through Dec 2017, changed 0.08% year-over-year, with the annual reading at -$8836.0 for FY2017, 101.87% down from the prior year.
  • Minority Interest was -$9007.0 for Q4 2017 at IGC Pharma, down from -$8854.0 in the prior quarter.
  • Over five years, Minority Interest peaked at $576803.0 in Q2 2014 and troughed at -$9007.0 in Q4 2017.
  • The 5-year median for Minority Interest is $523033.0 (2014), against an average of $393083.6.
  • Year-over-year, Minority Interest increased 6.96% in 2014 and then plummeted 102.1% in 2017.
  • A 5-year view of Minority Interest shows it stood at $531772.0 in 2013, then grew by 4.67% to $556612.0 in 2014, then rose by 2.35% to $569702.0 in 2015, then tumbled by 101.58% to -$9000.0 in 2016, then fell by 0.08% to -$9007.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Minority Interest are -$9007.0 (Q4 2017), -$8854.0 (Q3 2017), and -$8790.0 (Q2 2017).